Comparative Pharmacology
Head-to-head clinical analysis: VISTIDE versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VISTIDE versus VITRASERT.
VISTIDE vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cidofovir is a nucleotide analogue that inhibits viral DNA polymerase by incorporating into viral DNA and causing chain termination, with selectivity for cytomegalovirus (CMV) DNA polymerase.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
5 mg/kg intravenously once weekly for 2 consecutive weeks, then every other week thereafter.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, the half-life can extend to 5-10 hours or longer, necessitating dose adjustment based on creatinine clearance.
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Primarily renal excretion via glomerular filtration and active tubular secretion. Approximately 90-95% of the dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category C
Category C
Antiviral
Antiviral